TickerFiles

Aspire Biopharma Holdings, Inc. 10-K filing

Filed 2026-03-30 · Report date 2025-12-31 · 2025 FY

View Original SEC Filing

Filing metadata

Accession number
0001493152-26-013682
Form type
10-K
CIK
0001847345
Primary document
https://www.sec.gov/Archives/edgar/data/1847345/000149315226013682/form10-k.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Aspire Biopharma Holdings, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$6,202--
Cost Of Revenue$6,318--
Gross Profit$-116--
Operating Income$-19.4M--
Net Income$-24.5M--
Eps Diluted-16.38--
Total Assets$1.3M--
Total Liabilities$7.7M--
Shareholders Equity$-6.4M--
Operating Cash Flow$-4.9M--